Pacific Biosciences is trading 10.1% down at $2.10 on October 12, 2026, with no confirmed company-specific catalyst identified. - The latest company announcement found was its October 6 TychoBio collaboration, which does not explain the drop. - A report said the CFO’s October 6 stock sale was made under a prearranged trading plan and does not establish a new catalyst. - Broader markets were mixed: the Nasdaq was down 0.32%, while the Dow was up 0.35%. Available evidence does not clearly attribute the decline to company news or the overall market.